Table 4.

Multivariable analysis evaluating outcomes following AHCT in patients with AL from time of transplant

Effect	Hazard Ratio	95%CI_L	95%CI_U	P-value
Relapse/Progression
Bortezomib Induction (Main Effect)
No	1.00			<0.01
Yes	0.48	0.31	0.74	<0.01
Serum Creatinine Prior to AHCT
<2 mg/dl	1.00			0.04
≥2 mg/dl	1.78	1.02	3.10	0.04
Karnosky Score
≥90%	1.00			0.02
<90%	1.97	1.24	3.11	<0.01
Melphalan Dose (mg/m2)
200	1.00			0.02
100	2.45	1.22	4.92	0.01
140	2.08	1.22	3.55	<0.01
180	0.99	0.47	2.10	0.99
Progression-free Survival
Bortezomib Induction (Main Effect)
No	1.00			<0.01
Yes	0.47	0.32	0.69	<0.01
Serum Creatinine Prior to AHCT
<2 mg/dl	1.00			0.04
≥2 mg/dl	1.66	1.02	2.72	0.04
Karnosky Score
≥90%	1.00			<0.01
<90%	2.13	1.41	3.21	<0.01
Melphalan Dose (mg/m2)
200	1.00			<0.01
100	2.32	1.24	4.34	<0.01
140	2.09	1.30	3.36	<0.01
180	1.14	0.60	2.14	0.69
Overall Survival
Bortezomib Induction (Main Effect)
No	1.00			0.07
Yes	0.57	0.32	1.04	0.07
Melphalan Dose (mg/m2)
200	1.00			<0.01
100	3.93	1.65	9.42	<0.01
140	3.01	1.49	6.09	<0.01
180	1.05	0.34	3.23	0.93

AHCT, autologous hematopoietic cell transplantation